Linked Life Data

6634760

Source:http://linkedlifedata.com/resource/pubmed/id/6634760

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1983-12-20
pubmed:abstractText
The SIRS suppressor pathway is initiated by activation of Ly 2+ T lymphocytes by either con A or IFN beta. SIRS is a protein which has been purified and exists as two species with mol. wts. of 14,000 and 21,500. The target of SIRS is the macrophage and macrophages appear to oxidize or activate SIRS in a peroxide dependent process. Catalase blocks SIRS or IFN beta action by consuming H2O2 and levamisole blocks SIRS or IFN beta by preventing activation or oxidation of SIRS by H2O2. Other agents which block SIRS or IFN beta action include electron donors which can inactivate SIRSox. SIRSox is a potent inhibitor of immune responses and proliferation of normal and neoplastic cells. The mechanism of SIRSox-mediated inhibition of proliferation appears to involve oxidation or modification of protein sulfhydryls. Although the applicability of this pathway to the regulation of immune responses and cellular proliferation remains to be determined, both IFN beta and levamisole have been found to affect a wide variety of cellular processes. The involvement of both IFN beta and levamisole in the SIRS pathway suggests that this pathway may be an important host mechanism for regulating both immune responses and cellular proliferation in general.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-7742
pubmed:author
pubmed:issnType
Print
pubmed:volume
132B
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
335-44
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Properties of the SIRS suppressor pathway.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't